Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.31 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198143 | 0.87 | NOTUM (0.45) | NOTUMCA2CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL4876723 | 0.75 | NOTUM (0.38) | NOTUMCYP11B1CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL16975525 | 0.74 | KIF11 (0.37) | NOTUMCYP11B1CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL2360873 | 0.72 | KCNN4 (0.57) | NOTUMCA2CYP11B1CYP11B2ALDH1A1 | |
| Phenylboronic Acid SCHEMBL9403416 | 0.72 | CA4 (0.44) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL8987731 | 0.69 | NOTUM (0.42) | NOTUMCYP11B1CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL369213 | 0.69 | CA4 (0.39) | CA4CA6CA5ACA7ENPP2 | |
| Phenylboronic Acid SCHEMBL8628436 | 0.66 | ENPP2 (1.00) | CA4CA6CA5ACA7ENPP2 | |
| Phenylboronic Acid SCHEMBL4453 | 0.66 | — | — | |
| SCHEMBL3256000 | 0.66 | CA1 (0.43) | CA4CA6CA5ACA7ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868180-B2 | Process for the preparation of sartan derivatives and intermediates useful in such process | KRKA, D.D. NOVO MESTO (SI) | 2011-01-11 | — | — | US | disclosed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | disclosed |
| EP-1931655-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., Novo Mesto (SI) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039117-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., NOVO, MESTO (SI) | 2007-04-12 | — | — | WO | disclosed |
| EP-1764365-A1 | A process for the preparation of sartan derivates and intermediates useful in such process | KRKA, D.D., Novo Mesto (SI) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | CA4 997/4885CA6 474/4885CA5A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.